Here's the secret behind CSL's monster 42% return on equity

Breaking down CSL Limited's (ASX:CSL) monster returns on equity.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Last week I noted that blood product company CSL Limited (ASX: CSL) was building up a steady history of monster returns on equity (roe).

At 42% these returns are far above the 6% industry average hinting at a company with a strong, sustainable competitive advantage. But where is the high return coming from?

Breaking down return on equity

To see where CSL's huge 42% ROE comes from, we can break it out into three components using a method called DuPont analysis:

  • Net profit margin (Net Income ÷ Revenue) 0.22
  • Asset Turnover (Revenue ÷ Assets) 0.73
  • Equity Multiplier (Assets ÷ Shareholders' Equity) 2.64
  • Return on equity = (0.22) x (0.73) x (2.64) = 42%

Even by healthcare standards CSL's 42% ROE is impressive, with Cochlear Limited (ASX: COH) being one of the few companies to come close at 40%.

But when we break it down we can see that the big driver of the returns is in fact CSL's use of debt to fund assets; the high equity multiplier. Without this, if CSL didn't leverage its assets with borrowed money, ROE would only be 16%.

Why does CSL use debt, rather than fund growth from its strong cash flows? With borrowing costs so low it makes sense to use debt to fund moderate growth if the company knows it can generate new income above it's average cost of capital to pay it back.

CSL has strong cash flows to service its interest payments, but if a comparable investment had a higher unleveraged return, we may prefer to buy it.

Foolish takeaway

To me, CSL is to healthcare what Johnson & Johnson is to consumer products, or what Nestlé is to snack foods; a well-structured staple producer with low cyclical volatility and strong margins and volumes.

It's a company I would still love to own, and I will certainly be watching for any weakness in share price.

Motley Fool contributor Regan Pearson has no position in any of the stocks mentioned. You can follow him on Twitter @Regan_Invests. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »